NCT06455046View on ClinicalTrials.gov

Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

October 10, 2025

Study Completion Date

October 10, 2025

Conditions
Cervical Cancer Recurrent
Interventions
DRUG

AK104

PD-1/CTLA-4 bispecific antibody

DRUG

Recombinant Human Adenovirus 5 Injection

Recombinant Human Adenovirus 5 Injection

Trial Locations (1)

350011

RECRUITING

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
collaborator

Zhangzhou Municipal Hospital of Fujian Province

OTHER

lead

Fujian Cancer Hospital

OTHER_GOV